MX339858B - Compuestos novedosos como ligandos del receptor h3 de la histamina. - Google Patents

Compuestos novedosos como ligandos del receptor h3 de la histamina.

Info

Publication number
MX339858B
MX339858B MX2013009683A MX2013009683A MX339858B MX 339858 B MX339858 B MX 339858B MX 2013009683 A MX2013009683 A MX 2013009683A MX 2013009683 A MX2013009683 A MX 2013009683A MX 339858 B MX339858 B MX 339858B
Authority
MX
Mexico
Prior art keywords
novel compounds
histamine
receptor ligands
formula
pharmaceutically acceptable
Prior art date
Application number
MX2013009683A
Other languages
English (en)
Other versions
MX2013009683A (es
Inventor
Venkateswarlu Jasti
Anil Karbhari Shinde
Ramakrishna Nirogi
Pradeep Jayarajan
Ishtiyaque Ahmad
Ramasastri Kambhampati
Amol Dinakar Deshpande
Adi Reddy Dwarampudi
Narasimhareddy Gangadasari
Sangram Keshari Saraf
Vishwottam Nagaraj Kandikere
Mohmadsadik Abdulhamid Mulla
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MX2013009683A publication Critical patent/MX2013009683A/es
Publication of MX339858B publication Critical patent/MX339858B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se relaciona con compuestos novedosos de fórmula (I), y sus sales farmacéuticamente aceptables y composiciones que los contienen. (Ver Formula) La presente invención también se relaciona con un proceso para la preparación de los compuestos novedosos anteriores, y sus sales farmacéuticamente aceptables. Los compuestos de fórmula (I) son útiles en el tratamiento de varios trastornos que están relacionados con los receptores H3 de la Histamina.
MX2013009683A 2011-02-23 2011-06-07 Compuestos novedosos como ligandos del receptor h3 de la histamina. MX339858B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN520CH2011 2011-02-23
PCT/IN2011/000380 WO2012114348A1 (en) 2011-02-23 2011-06-07 Novel compounds as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
MX2013009683A MX2013009683A (es) 2013-10-28
MX339858B true MX339858B (es) 2016-06-15

Family

ID=54290090

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009683A MX339858B (es) 2011-02-23 2011-06-07 Compuestos novedosos como ligandos del receptor h3 de la histamina.

Country Status (27)

Country Link
US (1) US9079888B2 (es)
EP (1) EP2694492B1 (es)
JP (1) JP5805792B2 (es)
KR (1) KR101554407B1 (es)
CN (1) CN103443093B (es)
AP (1) AP3340A (es)
AU (1) AU2011360550B2 (es)
CA (1) CA2827567C (es)
CY (1) CY1116721T1 (es)
DK (1) DK2694492T3 (es)
EA (1) EA023260B1 (es)
ES (1) ES2548284T3 (es)
HK (1) HK1187613A1 (es)
HR (1) HRP20151003T1 (es)
HU (1) HUE025163T2 (es)
IL (1) IL228019A (es)
ME (1) ME02212B (es)
MX (1) MX339858B (es)
NZ (1) NZ614567A (es)
PL (1) PL2694492T3 (es)
PT (1) PT2694492E (es)
RS (1) RS54248B1 (es)
SG (1) SG192858A1 (es)
SI (1) SI2694492T1 (es)
SM (1) SMT201500238B (es)
WO (1) WO2012114348A1 (es)
ZA (1) ZA201306328B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
NZ728915A (en) 2014-08-16 2018-01-26 Suven Life Sciences Ltd Process for large scale production of n-[4-(1- cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride
HUE052003T2 (hu) * 2016-08-18 2021-04-28 Suven Life Sciences Ltd Hisztamin-3 receptor inverz agonisták kombinációja acetilkolinészteráz inhibitorokkal
SI3500306T1 (sl) * 2016-08-18 2020-11-30 Suven Life Sciences Limited Trojna kombinacija histamin-3 receptor inverznega agonista, inhibitorjev acetilholinesteraze in NMDA receptor antagonista
BR112020024264A2 (pt) * 2018-05-31 2021-02-23 Suven Life Sciences Limited agonista invertido do receptor de histamina-3, uso de um agonista invertido do receptor de histamina-3 para a fabricação de um medicamento e composição farmacêutica
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2023166349A2 (zh) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 苯基脲类衍生物及其医药用途
WO2023166351A1 (zh) * 2022-03-02 2023-09-07 杭州百诚医药科技股份有限公司 组胺h3受体抑制剂及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
PT1311482E (pt) * 2000-08-08 2007-04-30 Ortho Mcneil Pharm Inc Ariloxipiperidinas não imidazólicas como ligandos do receptor h3
WO2002076925A2 (en) * 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
MXPA05006567A (es) * 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
MXPA06011167A (es) * 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
CA2577061C (en) 2004-08-23 2014-02-18 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses
US8288389B2 (en) 2007-09-06 2012-10-16 Glaxo Group Limited Piperazine derivative having affinity for the histamine H3 receptor
RS52221B (en) * 2007-10-17 2012-10-31 Sanofi N-PHENYL-BIPYROLIDUM UREA SUBSTITUTED AND THE THERAPEUTIC USES thereof
WO2009100120A2 (en) 2008-02-04 2009-08-13 Neurogen Corporation Pyridinyl-substituted piperazinyl oxoethyl tetrahydropyrazolopyridines
CA2719985A1 (en) 2008-03-31 2009-10-08 Evotec Ag Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
CA2721303C (en) 2008-05-08 2016-06-28 Evotec Ag Azetidines and cyclobutanes as histamine h3 receptor antagonists
CA2739491A1 (en) * 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof

Also Published As

Publication number Publication date
SG192858A1 (en) 2013-09-30
MX2013009683A (es) 2013-10-28
PL2694492T3 (pl) 2015-12-31
RS54248B1 (en) 2016-02-29
EA023260B1 (ru) 2016-05-31
AP3340A (en) 2015-07-31
NZ614567A (en) 2014-07-25
EA201391211A1 (ru) 2014-06-30
WO2012114348A1 (en) 2012-08-30
HRP20151003T1 (hr) 2015-10-23
AP2013007088A0 (en) 2013-08-31
EP2694492B1 (en) 2015-07-29
CN103443093A (zh) 2013-12-11
AU2011360550B2 (en) 2015-04-09
US20140135304A1 (en) 2014-05-15
BR112013021496A2 (pt) 2019-08-06
DK2694492T3 (en) 2015-11-09
EP2694492A1 (en) 2014-02-12
ES2548284T3 (es) 2015-10-15
AU2011360550A1 (en) 2013-09-12
HK1187613A1 (en) 2014-04-11
CY1116721T1 (el) 2017-03-15
SMT201500238B (it) 2015-10-30
US9079888B2 (en) 2015-07-14
PT2694492E (pt) 2015-10-19
ME02212B (me) 2016-02-20
CA2827567A1 (en) 2012-08-30
CA2827567C (en) 2015-10-27
JP2014508761A (ja) 2014-04-10
KR20130133270A (ko) 2013-12-06
IL228019A0 (en) 2013-09-30
CN103443093B (zh) 2015-02-25
ZA201306328B (en) 2014-04-30
HUE025163T2 (en) 2016-02-29
JP5805792B2 (ja) 2015-11-10
IL228019A (en) 2015-11-30
KR101554407B1 (ko) 2015-09-18
SI2694492T1 (sl) 2015-11-30

Similar Documents

Publication Publication Date Title
MX2013014577A (es) Compuestos de heteroarilo como ligandos del receptor 5-ht4.
MX339858B (es) Compuestos novedosos como ligandos del receptor h3 de la histamina.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
TN2014000112A1 (en) Ep1 receptor ligands
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
MX2013013465A (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
MX2013013950A (es) Derivados de riperidina 3-espirociclicos como antagonistas de los receptores de grelina.
IN2014DN06964A (es)
MX2013006768A (es) Moduladores de receptor de glucagon.
MX362858B (es) Proceso para la preparacion de pemetrexed y sal de lisina del mismo.
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
EA201390327A1 (ru) Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов
MX2012007783A (es) Compuestos sulfona que actuan como ligandos del receptor 5-ht6.
WO2013048949A3 (en) Selective nr2b antagonists
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX337106B (es) Antagonistas no competitivos de receptores nicotinicos.
EA201590413A1 (ru) Соединения акриламида в качестве лигандов h-рецептора гистамина
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
MX364929B (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4.
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
MX2013007952A (es) Antagonistas no competitivos de receptores nicotinicos.
TN2013000122A1 (en) Oxadiazole inhibitors of leukotriene production

Legal Events

Date Code Title Description
FG Grant or registration